

**Table S1 Treatment history and clinical parameters for cohort of RMs used to isolate SHIVIG**

Monkey	Virus exposure	Other treatments	Viral RNA copies/ml		CD4 count	Number of months infected	Clinical status	Ref.
			Peak	Last				
RAo-8	SHIV-1157ip passage	-	$2.8 \times 10^7$	<50	624	110	systemic infection, LTNP	[12]
RCt-10	SHIV-1157ipd3N4	DNA prime: pJW-gp160-1157ip pJWSIVgag-pro pJWHIVtat protein boost: SHIV-1157ip gp160 AT-2-inactivated SIV HIV Tat	$2 \times 10^7$	<50	290	52	sacrificed due to acute pneumonia	unpub. data
RHo-10	SHIV-1157ipd3N4	-	$7.1 \times 10^7$	250	414	60	persistently viremic	unpub. data
RHy-9	SHIV-1157ip SHIV-1157ipd3N4	DNA prime: pJW-gp160-1048i pJWSIVgag-pro pJWHIVtat protein boost: HIV1084i gp160 SIV Gag-Pol particles HIV Tat	$6.3 \times 10^4$	<50	694	37	systemic infection, LTNP, sacrificed due to behavior problem	[14]
RJa-9	SHIV-1157ip oral titration	<i>S. mansoni</i>	$3.7 \times 10^6$	<50	596	102	systemic infection, LTNP	[13]
RLu-9	SHIV-1157ip SHIV-1157ipd3N4	HIV1084i gp160 SIV Gag-Pol particles HIV Tat	$7.8 \times 10^5$	<50	330	122	systemic infection, LTNP	[13]
RMf-9	SHIV-1157ip oral titration	<i>S. mansoni</i>	$7.2 \times 10^7$	<50	479	101	systemic infection, LTNP	[14]
RPo-10	SHIV-1157ip passage	-	$5 \times 10^7$	$2.1 \times 10^5$	485	54	sacrificed due to mycobacteriosis	[12]
RTs-7	SHIV-1157ip passage	-	$6.6 \times 10^5$	$3.7 \times 10^4$	14	87	systemic infection, death from AIDS	[12]